# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Bloomberg
EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised ...
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to...
Sanofi is set to invest up to $1.6 billion in its Frankfurt insulin production site, marking a significant win for Germany'...
Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MSFrexalimab high-dose arm obse...
- Reuters
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary dis...
Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia f...
The trial showed a greater proportion of those receiving weight-tiered higher dose Dupixent experienced significant improvement...